Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

Davide Rossi, Valeria Spina, Michaela Cerri, Silvia Rasi, Clara Deambrogi, Lorenzo De Paoli, Luca Laurenti, Rossana Maffei, Francesco Forconi, Francesco Bertoni, Emanuele Zucca, Claudio Agostinelli, Antonello Cabras, Marco Lucioni, Maurizio Martini, Michele Magni, Silvia Deaglio, Marco Ladetto, Josep F. Nomdedeu, Caroline Besson, Antonino Carbone, Stefano A. Pileri, Valter Gattei, and Gianluca Gaidano

Abstract

Purpose: Few biological prognosticators are useful for prediction of Richter syndrome (RS), representing the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. Stereotyped B-cell receptors (BCR) may have prognostic effect in CLL progression. We tested the prognostic effect of stereotyped BCR for predicting RS transformation.

Experimental Design: The prevalence of stereotyped BCR was compared in RS (n = 69) versus nontransformed CLL (n = 714) by a case-control analysis. Subsequently, the effect of stereotyped BCR at CLL diagnosis on risk of RS transformation was actuarially assessed in a consecutive CLL series (n = 753).

Results: RS (n = 69) displayed a higher prevalence of stereotyped BCR (P < 0.001) compared with nontransformed CLL. The actuarial risk of RS transformation was significantly higher in CLL carrying stereotyped BCR (P < 0.001). Among BCR subsets most represented in CLL, subset 8 using IGHV4-39/IGHD6-13/IGHJ5 carried the highest risk of RS transformation [hazard ratio (HR), 24.50; P < 0.001]. Multivariate analysis selected stereotyped BCR (HR, 3.33; P = 0.001) and IGHV4-39 usage (HR, 4.03; P = 0.004) as independent predictors of RS transformation. The combination of IGHV4-39 usage and stereotyped BCR in the same patient identified CLL with a very high risk of RS transformation (5-year risk, 68.7%). The risk carried by stereotyped BCR and IGHV4-39 usage was specific for RS transformation and had no effect on CLL progression without transformation.

Conclusions: Analysis of BCR features may help identify CLL patients at risk of RS. A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.

Richter syndrome (RS) represents the clinicopathologic transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma, mainly occurring as diffuse large B-cell lymphoma (DLBCL; refs. 1, 2). The risk of CLL transformation to RS is substantial, ranging from 3% to 16% (1–6).

The pathogenetic mechanisms underlying CLL transformation to RS are poorly understood (6–12). In CLL, immunogenetic findings suggest that antigen stimulation may be involved in disease development (13, 14). In fact, nonrandom combinations of specific immunoglobulin heavy chain (IGH) V-D-J

Authors’ Affiliations: 1Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 2Catholic University of the Sacred Heart, Rome, Italy; 3University of Modena and Reggio Emilia, Modena, Italy; 4University of Siena-AOUS, Siena, Italy; 5Oncology Institute of Southern Switzerland-IOSI, Bellinzona, Switzerland; 6Serafini Institute, University of Bologna, Bologna, Italy; 7Istituto Nazionale Tumori, Milan, Italy; 8University of Pavia, Pavia, Italy; 9University of Turin, Turin, Italy; 10Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 11Hôpital Bicêtre, Paris, France; and 12Centro di Riferimento Oncologico, Aviano, Italy

Received 12/18/08; revised 3/30/09; accepted 4/1/09; published Online First 6/9/09.

Grant support: PRIN 2006, Rome, Italy; Progetto Alfieri, Fondazione CRT, Turin, Italy; Ricerca Sanitaria Finalizzata, Regione Piemonte, Turin, Italy; Novara AIL Onlus, Novara, Italy; Associazione Italiana per la Ricerca sul Cancro, Milan, Italy; Istituto Oncologico Milan, Italy; Ricerca Finalizzata I.R.C.C.S. and U.S. Section 1734 solely to indicate this fact.
Translational Relevance

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. Because disease extent influences RS outcome, prompt recognition of RS may be clinically useful and may be improved by availability of biological predictors. Usage of stereotyped B-cell receptors (BCR) is a specific biological feature of CLL. We document that, at CLL diagnosis, stereotyped BCR usage is an independent risk factor of subsequent transformation to RS. Among subsets defined by stereotyped BCR, a specific subset using the IGHV4-39 gene carries a 24-fold increased risk of RS transformation. Combination of IGHV4-39 usage and stereotyped BCR in the same patient defines a very high risk of RS transformation (5-year risk, 68.7%). Analysis of BCR features may help identify CLL patients at risk of RS. A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.

Materials and Methods

Patients. The study was based on a multiinstitutional consecutive series of 753 CLL with typical slg low/CD5+/CD23+ phenotype and Matutes score of ≥3 (ref. 33; Supplementary Table S1), of which 39 had transformed to RS and 714 never developed clinical evidence of RS (median follow-up of the whole series, 41.1 months; median time to RS transformation, 23.0 months; median follow-up of CLL nontransformed to RS, 42.0 months). Thirty additional cases of RS were also collected. All RS cases (n = 69) had a previous or concomitant diagnosis of CLL that was defined according to International Workshop on Chronic Lymphocytic Leukaemia-National Cancer Institute (IWCLL-NCI) guidelines and was confirmed by a Matutes score of ≥3 in all cases (33–35). RS diagnosis was based on histology of lymph node or extranodal tissue excisional biopsies. All RS cases were classified as DLBCL according to the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues (36). In all 69 RS cases, the tissue used for molecular studies was the bioptic tissue used for RS diagnosis.

Study design. The design of the study was divided into three steps. The first step of the study consisted of a case-control analysis comparing prevalence of HCDR3 clustering in cases of RS (n = 69) versus CLL (n = 714) of the multiinstitutional consecutive series that were known not to have transformed to RS. IGHV-D-J gene usage, mutational status, and HCDR3 clustering of the nontransformed CLL used as control group were representative of the disease (Supplementary Tables S2, S3, S4, and S5).

The second step of the study consisted of an actuarial assessment of the effect of stereotyped HCDR3 at CLL diagnosis on the risk of subsequent transformation to RS. For this purpose, stereotyped HCDR3 used at CLL diagnosis by CLL leukemic cells were considered for the analysis. A multiinstitutional CLL cohort of 753 consecutive CLL, of which 39 had transformed to RS, was used for the actuarial study.

The third step of the study aimed at verifying whether HCDR3 subsets observed in RS also occurred in a consecutive series of de novo DLBCL (n = 63).

Patients provided informed consent in accordance with local institutional review board requirements and Declaration of Helsinki. The study was approved by the local institutional review board.

Analysis of IGHV-D-J, IGKV-J, and IGLV-J rearrangements. Rearrangements of IGHV-D-J and IGKV-J light chain genes were amplified with family-specific primers that hybridize to sequences in the IGHV, IGKV (IGKV) and IGGLV (IGLV) leader region, and framework region 1 (FR1) or FR2 in conjunction with the corresponding IGHJ, IGKJ, or IGLJ primers (37). PCR products were directly sequenced with the ABI PRISM BigDye Terminator v1.1 Ready Reaction Cycle Sequencing kit (Applied Biosystems) using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequences were aligned to ImMunoGeneTics sequence directory13 and considered mutated if homology to the corresponding germline gene was <98% (38, 39). The IGHD germline segment was assigned according to IMGT/Junction Analysis tool, following the established IMGT criteria.13 HCDR3 length was determined according to IMGT13 (21, 22).

HCDR3 clustering. The HCDR3 from 69 RS and 714 nontransformed CLL were aligned to the HCDR3 sequences from an Italian multiinstitutional CLL database (n = 862; ref. 25), public CLL databases (n = 1029; Supplementary Table S6), and the Murray database (n = 530; ref. 22).

For HCDR3-driven clustering, all in-frame IGHV-D-J rearrangements were converted into amino acid sequences and aligned according to the putative HCDR3 amino acid sequences using the multiple sequence alignment software ClustalX (1.83). Subsets identified as having stereotyped HCDR3 amino acid sequences were those characterized by an alignment score of ≥60 and an amino acid identity of ≥60%. Subsets that had not been previously described and that were composed of only two HCDR3s were termed as provisional and considered only if they shared junction residues, used the same IGH-D-J genes, or displayed a restricted light chain usage.

Subset nomenclature was according to Murray et al. (22). For the purpose of this study, subsets not previously included in the Murray nomenclature system were assigned an alphabet letter.

EBV analysis. Analysis of EBV infection was done by PCR and/or in situ hybridization of EBER transcripts, as previously reported (37).

**Table 1. Variables at CLL diagnosis predicting RS transformation by univariate analysis**

<table>
<thead>
<tr>
<th>Event</th>
<th>Events/n</th>
<th>5-y risk</th>
<th>SE</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0-II</td>
<td>28/664</td>
<td>5.0%</td>
<td>1.0%</td>
<td>0.001</td>
</tr>
<tr>
<td>Stage III-IV</td>
<td>11/89</td>
<td>17.4%</td>
<td>5.2%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CD38, &lt;30%</td>
<td>12/445</td>
<td>3.1%</td>
<td>1.1%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CD38, &gt;30%</td>
<td>23/190</td>
<td>15.5%</td>
<td>3.3%</td>
<td>0.034</td>
</tr>
<tr>
<td>IGHV homology, &lt;98%</td>
<td>11/449</td>
<td>3.1%</td>
<td>1.0%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IGHV homology, ≥98%</td>
<td>28/304</td>
<td>11.4%</td>
<td>2.3%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No IGHV4-39</td>
<td>33/733</td>
<td>5.6%</td>
<td>1.1%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IGHV4-39</td>
<td>6/20</td>
<td>35.4%</td>
<td>13.5%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stereotyped HCDR3</td>
<td>18/579</td>
<td>4.0%</td>
<td>1.0%</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: Events/n, number of events over number of patients; 5-y risk, 5-year risk of transformation calculated by Kaplan-Meier method; P, P value calculated by log-rank test.
Variables not associated with RS transformation in multivariate analysis included IGHV homology ($P = 0.166$) and Rai stage ($P = 0.087$).

Stereotyped HCDR3 using IGHV4-39 identifies a subgroup of CLL at very high risk of RS transformation. The prevalence of stereotypic HCDR3 was stratified according to IGHV gene usage in RS and nontransformed CLL. The HCDR3 of all RS using IGHV4-39 (six of six, 100%) entered a subset compared with only 2 of 14 (14.3%) HCDR3 of nontransformed CLL using IGHV4-39 ($P = 0.001$; Supplementary Tables S7 and S8).

The observation that all RS using IGHV4-39 carried stereotyped HCDR3 prompted investigation of the interaction between IGHV4-39 usage and stereotyped HCDR3 in the model. Multivariate Cox analysis selected the interaction between IGHV4-39 usage and stereotyped HCDR3 as the strongest independent predictor of RS transformation (HR, 4.76; 95% CI, 1.76-12.88; $P = 0.002$; Table 2).

Accordingly, bivariate analysis segregated three risk categories (Fig. 2): (a) CLL using both IGHV4-39 and stereotyped HCDR3 represented the disease category with the highest risk of transformation (events/n, 6/8; 5-year risk, 68.7%); (b) CLL using stereotyped HCDR3 but without IGHV4-39 showed an intermediate risk of transformation (events/n, 15/178; 5-year risk, 9.9%); and (c) CLL using a nonstereotyped HCDR3, independent of IGHV4-39 usage, showed the lowest risk of RS transformation.

Table 2. Multivariate analysis for RS transformation

<table>
<thead>
<tr>
<th>Biological and clinical variables*</th>
<th>HR</th>
<th>95% CI</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGHV4-39</td>
<td>4.03</td>
<td>1.57-10.32</td>
<td>0.004</td>
</tr>
<tr>
<td>Stereotyped HCDR3</td>
<td>3.33</td>
<td>1.63-6.80</td>
<td>0.001</td>
</tr>
<tr>
<td>CD38 expression $\geq$30%</td>
<td>3.34</td>
<td>1.61-6.92</td>
<td>0.001</td>
</tr>
<tr>
<td>Interaction analysis†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGHV4-39 stereotyped HCDR3</td>
<td>4.76</td>
<td>1.76-12.88</td>
<td>0.002</td>
</tr>
<tr>
<td>CD38 expression $\geq$30%</td>
<td>3.11</td>
<td>1.50-6.48</td>
<td>0.002</td>
</tr>
<tr>
<td>Stereotyped HCDR3</td>
<td>3.16</td>
<td>1.50-6.64</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Abbreviation: $P$, $P$ value calculated by Cox analysis.

*Covariates at CLL diagnosis that entered the analysis were IGHV4-39 usage versus no IGHV4-39 usage, stereotyped HCDR3 versus no stereotyped HCDR3, IGHV gene homology $\geq$98% versus IGHV gene homology $<98$%, CD38 expression $\geq$30% versus CD38 expression $<30$%, and Rai stage 0-II versus Rai stage III-IV.

†Covariates at CLL diagnosis that entered the analysis were IGHV4-39 usage versus no IGHV4-39 usage, stereotyped HCDR3 versus no stereotyped HCDR3, IGHV gene homology $\geq$98% versus IGHV gene homology $<98$%, CD38 expression $\geq$30% versus CD38 expression $<30$%, and Rai stage 0-II versus Rai stage III-IV, and IGHV4-39 stereotyped HCDR3 interaction.
IGHV4-39 (seven of eight cases) composed by cases belonging to HCDR3 using both investigation of subset composition of the high-risk category. Results of the bivariate analysis prompted transformation. 555; 5-year risk, 4.2%, respectively).

IGHV with other transformation (5-yrisk, 68.7%). CLL using stereotyped HCDR3 in combination and stereotyped HCDR3 represent the subgroup with the highest risk of transformation (5-yrisk, 9.9%). CLL using a nonstereotyped HCDR3, independent of IGHV4-39 usage, showed the lowest risk of RS transformation (5-yrisk, 0 and 5-yrisk, 4.2%, respectively).

**CLL using HCDR3 subset 8 carry the highest risk of RS transformation.** Results of the bivariate analysis prompted investigation of subset composition of the high-risk category using both IGHV4-39 and stereotyped HCDR3. This group of CLL at high risk of RS transformation was almost exclusively (seven of eight cases) composed by cases belonging to HCDR3 subset 8 and harboring the rearrangement of unmutated IGHV4-39/IGHD6-13/IGHJ5 genes. The remaining case belonged to HCDR3 subset 10 harboring the rearrangement of unmutated IGHV4-39/IGHD2-2/IGHJ6 genes.

On these bases, we asessed the association between subset 8 and RS. HCDR3 subset 8 showed a strong association with RS both in the case-control analysis and the actuarial analysis. In fact, by case control analysis, HCDR3 subset 8 was the sole HCDR3 subset preferentially used by RS with stereotyped HCDR3 (5 of 34, 14.7%) compared with nontransformed CLL with stereotyped HCDR3 (2 of 152, 1.3%; P = 0.002; Supplementary Table S5). By actuarial univariate analysis, HCDR3 subset 8 usage at CLL diagnosis associated with the highest risk of transformation (events/n, 5/7; 5-year risk, 64.3%; SE, 19.8%; HR, 24.50; P < 0.001; Supplementary Fig. S1). Multivariate Cox analysis confirmed that usage of HCDR3 subset 8 is an independent risk factor of RS transformation (HR, 3.78; 95% CI, 1.33-10.75; P = 0.013) after adjustment for CD38 expression (HR, 3.32; 95% CI, 1.59-6.92; P = 0.001), stereotyped HCDR3 (HR, 3.30; 95% CI, 1.60-6.79; P = 0.001), IGHV homology (P = 0.158), and Rai stage (P = 0.077).

According to bivariate analysis (Fig. 2), CLL using stereotyped HCDR3 but without IGHV4-39 showed an intermediate risk of RS transformation. This group of CLL was composed by a variety of subsets (n = 60), of which the most represented (at least five cases per subset) were subset 1 (n = 11), subset 2 (n = 13), subset 3 (n = 11), subset 4 (n = 9), subset 6 (n = 5), subset 7 (n = 16), subset 9 (n = 5), and subset 59 (n = 5). Overall, the most represented subsets accounted for 75 of 165 (45.4%) CLLs using stereotyped HCDR3 without IGHV4-39.

The risk of transformation to RS was heterogeneous when considering the most represented subsets (Supplementary Fig. S1). Subset 1 (events/n, 3/11; 5-year risk, 36.4%; SE, 17.7%; HR, 11.95; P < 0.001), subset 6 (events/n, 1/5; 5-year risk, 33.3%; SE, 27.2%; HR, 10.53; P = 0.022), subset 7 (events/n, 3/16; 5-year risk, 16.9%; SE, 11.0%; HR, 5.14; P = 0.009), and subset 59 (events/n, 1/5; 5-year risk, 20.0%; SE, 17.9%; HR, 7.53; P = 0.050) carried a higher risk of transformation compared with CLL without stereotyped HCDR3 (Supplementary Fig. S1). Conversely, subset 2 (events/n, 1/13; 5-year risk, 11.1%; SE, 10.5%; HR, 2.86; P = 0.306), subset 3, subset 4, and subset 9 (5-year risk, 0 and P > 0.05 in all instances) did not display an increased risk of RS transformation compared with CLL without stereotyped HCDR3 (Supplementary Fig. S1).

**The risk carried by stereotyped HCDR3 and by subset 8 at CLL diagnosis is specific for RS transformation and has no effect on other types of CLL progression.** Because transformation to RS and progression to symptomatic disease according to IWCLL-NCI guidelines are distinct events in CLL (34, 35), we also evaluated the effect of stereotyped HCDR3 and of IGHV4-39 usage on risk of CLL progression without transformation. Time to progression did not differ between CLL with stereotyped HCDR3 and CLL without stereotyped HCDR3 after adjustment for IGHV homology of ≥98% or <98% (P = 0.934 and P = 0.415, respectively). Also, time to progression did not differ between CLL harboring IGHV4-39 and CLL without IGHV4-39 (P = 0.711).

We then compared the effect of specific HCDR3 subsets on risk of transformation to RS and on risk of progression without transformation. Subset 8 using IGHV4-39 emerged as a strong predictor of RS transformation (HR, 24.50; P < 0.001) but did not predict CLL progression (P = 0.081). Conversely, subset 2 using IGHV3-21, which, as expected, was a risk factor for CLL progression (HR, 2.81; P = 0.002; refs. 14, 43), did not predict RS transformation (P = 0.306). Finally, subset 4 using IGHV4-34 and considered a benign subset (20), predicted neither RS transformation (P = 0.985) nor CLL progression (P = 0.089).

**Recurrent cytogenetic findings associate with RS transformation in CLL harboring stereotyped HCDR3.** FISH karyotype of the CLL phase was available in 596 cases, including 30 cases transformed to RS. The distribution of FISH abnormalities was assessed in the HCDR3 subsets most represented in our series. CLL belonging to subset 8, which used IGHV4-39 and displayed the highest risk of RS transformation, carried a recurrent cytogenetic pattern represented by +12 as the sole cytogenetic abnormality in four of five (80.0%) cases, all of which had transformed to RS. None of the subset 8 CLL with +12 showed translocation of the IGH locus or translocation of BCL-3. Conversely, CLL belonging to subset 4, which used IGHV4-34 and displayed no risk of RS transformation, carried a favorable FISH karyotype (del13q14) in all cases (n = 7).

**Stereotyped HCDR3 of RS are not observed in de novo DBCL.** To define whether stereotyped HCDR3 observed in RS occur also in primary aggressive B-cell non–Hodgkin's
lymphoma, we tested 63 cases of de novo DLBCL for HCDR3 clustering. Overall, stereotyped HCDR3 observed in RS occurred only sporadically in de novo DLBCL. In particular, (a) the HCDR3 of a single case of de novo DLBCL entered a RS subset, namely subset 7 (Supplementary Table S9); (b) none of the de novo DLBCL carried a stereotyped HCDR3 belonging to subset 8 using IGHV4-39; and (c) none of the de novo DLBCL clustered with another de novo DLBCL, whereas 12 of 69 (17.3%) RS clustered with another RS (P = 0.001). These data suggest that HCDR3 clustering observed in RS is exceptional in de novo DLBCL.

Discussion

The rationale of the study was 2-fold: (a) assess the role of BCR in RS and (b) verify whether stereotyped HCDR3 at diagnosis may help in the identification of CLL subgroups at high risk of subsequent RS transformation. We document that (a) RS carry stereotyped HCDR3 at a very high frequency, (b) stereotyped HCDR3 at CLL diagnosis is an independent risk factor of RS transformation, and (c) the risk of RS transformation depends upon specific subsets. In particular, HCDR3 subset 8 identifies CLL with a very high risk of transformation.

In CLL, the finding of stereotyped HCDR3 in 20% to 25% of cases coupled to the binding of specific antigens by some stereotyped HCDR3 have led to imply the role of antigen stimulation in leukemogenesis (13–26). In the context of RS, this hypothesis is further reinforced by (a) the frequency (~50%) of stereotyped HCDR3, significantly higher than in nontransformed CLL; (b) the preferential usage of IGHV4-39 gene; and (c) the overrepresentation of a specific HCDR3 subset (subset 8) using the IGHV4-39/D6-13/J5 rearrangement. Notably, our review of all IGHV-D-J rearrangements used by RS and reported in the literature also documents (a) frequent usage of IGHV4-39 (all RS cases, 7 of 55, 12.7%; IGHV unmutated RS, 7/47, 15.2%) with a prevalence that is similar to that observed in our cohort (P = 0.467 when comparing all RS from our series versus all RS from the literature; P = 0.703 when comparing IGHV unmutated RS from our series versus IGHV unmutated RS from the literature) and (b) stereotyped HCDR3 belonging to subset 8 in a fraction of cases (27–32). CLL using HCDR3 subset 8 have been shown to bind (auto)antigens associated with apoptosis and oxidation (44).

Biased usage of stereotyped HCDR3 and subset 8 in RS is confirmed also when an independent CLL cohort, previously published by Murray et al. (22), is used as control group. Prevalence of stereotyped HCDR3 is higher in RS compared with the CLL cohort of Murray et al. (22) when considering all cases (P < 0.001), cases with IGHV homology of ≥98% (P < 0.001), and cases with IGHV homology of <98% (P = 0.051). Also, HCDR3 subset 8 is the sole HCDR3 subset preferentially used by RS compared with the CLL cohort of Murray et al. (ref. 22; P < 0.001).

Our data show that stereotyped HCDR3 does not represent a surrogate of IGHV homology of ≥98% when considering RS transformation as an end point. In fact, CLL with stereotyped HCDR3 and IGHV homology of ≥98% showed a significantly higher risk of transformation compared with CLL with IGHV homology of ≥98% but without stereotyped HCDR3. Also, stereotyped HCDR3 is selected as an independent predictor of RS transformation in multivariate analysis after adjusting for IGHV homology of ≥98% and other potentially confounding covariates. Finally, the risk of RS transformation associated with the most represented subsets, including HCDR3 subset 8, is not affected by IGHV homology.

The effect of stereotyped HCDR3 usage in CLL progression and survival is heterogeneous and may depend upon specific subsets (21). Such heterogeneity is observed also in the setting of RS transformation. In fact, some HCDR3 subsets, including subset 8, are associated with RS transformation, whereas other HCDR3 subsets, including the benign subset 4 (21), display a negligible risk of RS.

The spectrum of HCDR3 subsets that are at risk of RS transformation apparently differs from the spectrum of HCDR3 subsets that are at risk of progression. In fact, HCDR3 subset 8 using IGHV4-39 is a strong predictor of RS transformation but has no significant effect on CLL progression. In contrast, subset 2 using IGHV3-21, which is a well-known risk factor of CLL progression (15, 43), failed to predict RS transformation. These observations reinforce the notion that biological and clinical risk factors of disease transformation to RS differ from risk factors of disease progression according to IWCLL-NCI guidelines (6).

The current definition of RS does not take into account the clonal relationship of RS with the original CLL clone (1, 2, 34–36). Accordingly, our study included clonally related RS, as well as RS for whom clonal relationship is unknown, and clonally unrelated RS. Subgroup analysis documented that IGHV4-39 usage and stereotypic HCDR3 are predictive of transformation also when the model is applied separately to clonally related RS and to RS for whom clonal relationship is unknown (data not shown). Due to the low number of cases (n = 6), no conclusion can be drawn from the subanalysis of clonally unrelated RS.

The heterogeneous outcome of specific HCDR3 subsets may depend upon their genetic profile (45). In the context of RS transformation, HCDR3 may identify CLL subsets with specific genetic features that increase the risk of RS. In our series, CLL belonging to HCDR3 subset 8 showed the highest risk of RS transformation and displayed the highest prevalence of +12 as the sole cytogenetic abnormality. The association between +12 and HCDR3 subset 8 has also been described in an independent CLL series that, however, did not include RS (45). Several lines of evidence suggest the involvement of +12 in RS transformation. First, RS frequently harbor +12 (1, 8, 46, 47). Second, +12 in the absence of del13q14 at diagnosis identifies a CLL subgroup at risk of RS transformation (6). Third, in our series, +12 (HR, 4.33; 95% CI, 1.33–14.08; P = 0.015) and del17p13 (HR, 4.89; 95% CI, 1.43–16.73; P = 0.011) were the sole FISH lesions associated with a significantly increased risk of subsequent transformation to RS.

Although a previous report linked usage of IGHV4-39 subset 8 with t(14;19) translocation in CLL, in our series BCL-3 translocation was not detected in any IGHV4-39 subset 8 CLL (48). This discrepancy might be due to the fact that our study included only CLL with a typical sIg low/CD5+/CD23+ phenotype and a Matutes score of >3 (33), whereas most CLLs harboring t(14;19) translocation have an atypical phenotype (48–50).

Only few biological markers available for predicting CLL progression have been shown to be useful for RS prediction (6, 11). HCDR3 subset 8 and more in general HCDR3 subset usage may be appropriate biological markers for RS prediction.
because (a) these markers are independent predictors of RS transformation after adjusting for other biological and clinical risk factors and importantly (b) virtually all CLL using HCDR3 subset 8 ultimately transform to RS.

The identification of CLL patients belonging to HCDR3 subset 8 may be feasible whenever IGHV-D-J usage is known. In this specific context, knowledge of IGHV-D-J usage may surrogately cluster analysis for the identification of CLL belonging to subset 8. In fact, in the database used for this study and comprising 3204 CLL IGHV-D-J rearrangements, usage of IGHV4-39/D6-13/J5 identifies CLL belonging to subset 8 with a sensitivity of 100% and a specificity of 100% (not shown).

Discourse extent is known to influence outcome of RS patients (5). Also, RS treatment requires dedicated treatment approaches, because regimens designed for CLL have been shown to be of little benefit for this disease (1–5, 51–53).

These observations suggest that prompt recognition of RS transformation may be clinically useful. Although at present it would be premature to use BCR features for tailoring RS treatment, a close monitoring and a careful biopsy policy may be of help for early recognition of RS transformation in patients carrying stereotyped HCDR3, particularly if belonging to subset 8.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Kostas Stamatopoulos, G. Papanicolaou Hospital, Thessaloniki, Greece, for critically reading the manuscript.

References

Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

Davide Rossi, Valeria Spina, Michaela Cerri, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/13/4415

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/06/15/1078-0432.CCR-08-3266.DC1

Cited articles
This article cites 52 articles, 28 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/13/4415.full#ref-list-1

Citing articles
This article has been cited by 21 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/15/13/4415.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.